Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2015 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Gastroparesis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Diabetic Gastroparesis - Pipeline Review, H1 2015', provides an overview of the Diabetic Gastroparesis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Gastroparesis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diabetic Gastroparesis Overview 7 Therapeutics Development 8 Pipeline Products for Diabetic Gastroparesis - Overview 8 Pipeline Products for Diabetic Gastroparesis - Comparative Analysis 9 Diabetic Gastroparesis - Therapeutics under Development by Companies 10 Diabetic Gastroparesis - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Diabetic Gastroparesis - Products under Development by Companies 14 Diabetic Gastroparesis - Companies Involved in Therapeutics Development 15 Cempra, Inc. 15 Evoke Pharma, Inc. 16 GlaxoSmithKline plc 17 Ironwood Pharmaceuticals, Inc. 18 Rhythm Pharmaceuticals 19 Shire Plc 20 Targacept, Inc. 21 Diabetic Gastroparesis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 camicinal - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ETX-101 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ETX-301 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 IW-9179 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 metoclopramide hydrochloride - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 prucalopride succinate - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 relamorelin - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 TC-6499 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 velusetrag - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Diabetic Gastroparesis - Recent Pipeline Updates 46 Diabetic Gastroparesis - Dormant Projects 53 Diabetic Gastroparesis - Discontinued Products 54 Diabetic Gastroparesis - Product Development Milestones 55 Featured News & Press Releases 55 Feb 02, 2015: Evoke Pharma Outlines Progress on Clinical Program 55 Dec 09, 2014: Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis 55 Dec 02, 2014: Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study 56 Sep 09, 2014: Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001 57 Aug 12, 2014: Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001 57 Jun 25, 2014: Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis 57 May 28, 2014: Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank 58 May 06, 2014: Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis 59 Jan 22, 2014: Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 60 Oct 15, 2013: Targacept Scientists to Present Data On TC-6499 at Society for Neuroscience Satellite Meeting 60 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables Number of Products under Development for Diabetic Gastroparesis, H1 2015 8 Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Diabetic Gastroparesis - Pipeline by Cempra, Inc., H1 2015 15 Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H1 2015 16 Diabetic Gastroparesis - Pipeline by GlaxoSmithKline plc, H1 2015 17 Diabetic Gastroparesis - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 18 Diabetic Gastroparesis - Pipeline by Rhythm Pharmaceuticals, H1 2015 19 Diabetic Gastroparesis - Pipeline by Shire Plc, H1 2015 20 Diabetic Gastroparesis - Pipeline by Targacept, Inc., H1 2015 21 Assessment by Monotherapy Products, H1 2015 22 Number of Products by Stage and Target, H1 2015 24 Number of Products by Stage and Mechanism of Action, H1 2015 26 Number of Products by Stage and Route of Administration, H1 2015 28 Number of Products by Stage and Molecule Type, H1 2015 30 Diabetic Gastroparesis Therapeutics - Recent Pipeline Updates, H1 2015 46 Diabetic Gastroparesis - Dormant Projects, H1 2015 53 Diabetic Gastroparesis - Discontinued Products, H1 2015 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
